These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9419193)

  • 21. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
    Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
    Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children.
    Ku CC; King CC; Lin CY; Hsu HC; Chen LY; Yueh YY; Chang GJ
    J Med Virol; 1994 Oct; 44(2):122-31. PubMed ID: 7852952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A large-scale study on the safety and epidemiological efficacy of Japanese encephalitis (JE) live vaccine (SA14-14-2) in the JE endemic areas].
    Zhou B; Jia L; Xu X
    Zhonghua Liu Xing Bing Xue Za Zhi; 1999 Feb; 20(1):38-41. PubMed ID: 10682513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial.
    Feroldi E; Pancharoen C; Kosalaraksa P; Watanaveeradej V; Phirangkul K; Capeding MR; Boaz M; Gailhardou S; Bouckenooghe A
    Hum Vaccin Immunother; 2012 Jul; 8(7):929-37. PubMed ID: 22777096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children.
    Chokephaibulkit K; Houillon G; Feroldi E; Bouckenooghe A
    Expert Rev Vaccines; 2016; 15(2):153-66. PubMed ID: 26588242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.
    Kim DS; Jang GC; Cha SH; Choi SH; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Bang J; Naimi Z; Bouckenooghe A; Bosch-Castells V; Houillon G
    Pediatr Infect Dis J; 2016 Feb; 35(2):e60-4. PubMed ID: 26535878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of wild-type and vaccine strains of Japanese encephalitis virus and the effect of haplotype restriction on murine immune responses.
    Wills MR; Singh BK; Debnath NC; Barrett AD
    Vaccine; 1993; 11(7):761-6. PubMed ID: 8342323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial.
    Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Sabchareon A; Pancharoen C; Bouckenooghe A; Gailhardou S; Boaz M; Feroldi E
    Pediatr Infect Dis J; 2010 Dec; 29(12):1111-7. PubMed ID: 20856164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.
    Yun KW; Lee HJ; Kang JH; Eun BW; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    BMC Infect Dis; 2015 Jan; 15():7. PubMed ID: 25567119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Japanese encephalitis. Inactivated Japanese encephalitis virus vaccine.
    Wkly Epidemiol Rec; 1994 Apr; 69(16):113-8. PubMed ID: 8003406
    [No Abstract]   [Full Text] [Related]  

  • 32. The efficacy of Japanese encephalitis vaccine in Henan, China: a case-control study.
    Luo D; Yin H; Xili L; Song J; Wang Z
    Southeast Asian J Trop Med Public Health; 1994 Dec; 25(4):643-6. PubMed ID: 7667706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current recommendations for the Japanese encephalitis vaccine.
    Chen HL; Chang JK; Tang RB
    J Chin Med Assoc; 2015 May; 78(5):271-5. PubMed ID: 25841620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: A single-arm, single-center study.
    Vu TD; Nguyen QD; Tran HTA; Bosch-Castells V; Zocchetti C; Houillon G
    Int J Infect Dis; 2018 Jan; 66():137-142. PubMed ID: 29081368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lot-to-lot consistency of live attenuated SA 14-14-2 Japanese encephalitis vaccine manufactured in a good manufacturing practice facility and non-inferiority with respect to an earlier product.
    Zaman K; Naser AM; Power M; Yaich M; Zhang L; Ginsburg AS; Luby SP; Rahman M; Hills S; Bhardwaj M; Flores J
    Vaccine; 2014 Oct; 32(46):6061-6. PubMed ID: 25239483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: immunogenicity and safety of vaccine administered in two dosing regimens.
    Defraites RF; Gambel JM; Hoke CH; Sanchez JL; Withers BG; Karabatsos N; Shope RE; Tirrell S; Yoshida I; Takagi M; Meschievitz CK; Tsai TF
    Am J Trop Med Hyg; 1999 Aug; 61(2):288-93. PubMed ID: 10463681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Japanese encephalitis protein vaccine candidates expressing neutralizing epitope and M.T hsp70 induce virus-specific memory B cells and long-lasting antibodies in swine.
    Fei-fei G; Jian W; Feng X; Li-ping S; Quan-yun S; Jin-ping Z; Pu-yan C; Pei-hong L
    Vaccine; 2008 Oct; 26(44):5590-4. PubMed ID: 18761388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus.
    Cao L; Fu S; Gao X; Li M; Cui S; Li X; Cao Y; Lei W; Lu Z; He Y; Wang H; Yan J; Gao GF; Liang G
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004686. PubMed ID: 27139722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune response in mice infected with the attenuated Japanese encephalitis vaccine strain SA14-14-2.
    Lee T; Komiya T; Watanabe K; Aizawa C; Hashimoto H
    Acta Virol; 1995 Jun; 39(3):161-4. PubMed ID: 8578998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Analysis on the immuno-effects of two different Japanese encephalitis virus vaccines].
    Guo W; Li L; Wu Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 1998 Apr; 19(2):97-9. PubMed ID: 10322719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.